Related references
Note: Only part of the references are listed.Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases
Loes van Keimpema et al.
LIVER INTERNATIONAL (2011)
Therapeutic mTOR Inhibition in Autosomal Dominant Polycystic Kidney Disease: What Is the Appropriate Serum Level?
G. Canaud et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2010)
Congenital fibrocystic liver diseases
Joost P. H. Drenth et al.
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2010)
Secondary and tertiary structure modeling reveals effects of novel mutations in polycystic liver disease genes PRKCSH and SEC63
E. Waanders et al.
CLINICAL GENETICS (2010)
Prospects for mTOR Inhibitor Use in Patients with Polycystic Kidney Disease and Hamartomatous Diseases
Vicente E. Torres et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
Reducing Polycystic Liver Volume in ADPKD: Effects of Somatostatin Analogue Octreotide
Anna Caroli et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
Polycystic liver diseases
P. Onori et al.
DIGESTIVE AND LIVER DISEASE (2010)
ERK1/2-Dependent Vascular Endothelial Growth Factor Signaling Sustains Cyst Growth in Polycystin-2 Defective Mice
Carlo Spirli et al.
GASTROENTEROLOGY (2010)
Congenital disorders of glycosylation in hepatology: The example of polycystic liver disease
Manoe J. Janssen et al.
JOURNAL OF HEPATOLOGY (2010)
Rapamycin Ameliorates PKD Resulting from Conditional Inactivation of Pkd1
Jonathan M. Shillingford et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
Randomized Intervention Studies in Human Polycystic Kidney and Liver Disease
Robert W. Schrier
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
Randomized Clinical Trial of Long-Acting Somatostatin for Autosomal Dominant Polycystic Kidney and Liver Disease
Marie C. Hogan et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
Sirolimus Therapy to Halt the Progression of ADPKD
Norberto Perico et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease
Iram Zafar et al.
KIDNEY INTERNATIONAL (2010)
Effect of octreotide on polycystic liver volume
Loes van Keimpema et al.
LIVER INTERNATIONAL (2010)
mTOR Inhibitors in Polycystic Kidney Disease
Terry Watnick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Sirolimus and Kidney Growth in Autosomal Dominant Polycystic Kidney Disease
Andreas L. Serra et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Everolimus in Patients with Autosomal Dominant Polycystic Kidney Disease
Gerd Walz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Treatment of polycystic liver disease
L. van Keimpema et al.
BRITISH JOURNAL OF SURGERY (2009)
Liver Cyst Cytokines Promote Endothelial Cell Proliferation and Development
Kelley S. Brodsky et al.
EXPERIMENTAL BIOLOGY AND MEDICINE (2009)
Lanreotide reduces the volume of polycystic liver: A randomized, double-blind, placebo-controlled trial
Loes Van Keimpema et al.
GASTROENTEROLOGY (2009)
Autosomal dominant polycystic kidney disease: the last 3 years
Vicente E. Torres et al.
KIDNEY INTERNATIONAL (2009)
Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease
Ming Wu et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2009)
Lanreotide Autogel (R) - A review of its use in the management of acromegaly
Jamie D. Croxtall et al.
DRUGS (2008)
Somatostatin analogues reduce liver volume in polycystic liver disease
L. van Keimpema et al.
GUT (2008)
Sirolimus reduces polycystic liver volume in ADPKD patients
Qi Qian et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2008)
Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3′,5′-cyclic monophosphate
Tatyana V. Masyuk et al.
GASTROENTEROLOGY (2007)
Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease
P Ruggenenti et al.
KIDNEY INTERNATIONAL (2005)
Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles
B Astruc et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Somatostatin stimulates ductal bile absorption and inhibits ductal bile secretion in mice via SSTR2 on cholangiocytes
AY Gong et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2003)
Regulation and deregulation of cholangiocyte proliferation
D Alvaro et al.
JOURNAL OF HEPATOLOGY (2000)
Share Paper
